Tenax Therapeutics announced two agreements with Orion to advance its oral levosimendan program. The parties entered a Supply Agreement for Orion to manufacture and supply the oral product for development and, if approved, commercialization, including cost-sharing for scale-up and defined operational terms. Concurrently, they executed a Sixth Amendment to their License Agreement, extending the U.S. regulatory approval milestone to December 31, 2035, and adding information and cybersecurity requirements. Together, the deals aim to secure manufacturing continuity while maintaining the partnership framework and deferring a termination right tied to the milestone.
Agreement 1: Tenax Therapeutics Finalizes Orion Supply Pact for Oral Levosimendan With Multi-Year Term
- Agreement type: Manufacturing and supply agreement for orally administered levosimendan
- Counterparty: Orion
- Signed / Effective: Jun 29 2026 / Jun 29 2026
- Duration / Termination: 5 years from first delivery; auto 3-year renewals
- Reason: Secure primary supply of oral levosimendan
Agreement 2: Tenax Therapeutics Extends Levosimendan License Milestone to 2035 in Sixth Amendment With Orion
- Agreement type: Sixth Amendment to License Agreement for levosimendan
- Counterparty: Orion
- Signed / Effective: Jun 29 2026 / Jun 29 2026
- Duration / Termination: Milestone deadline extended to Dec 31 2035
- Reason: Extend U.S. approval milestone and align cybersecurity requirements
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.